182 unknown, 141 recruiting, 82 not yet recruiting, 58 completed. 372 Phase 2, 74 Phase 1, 65 Phase 3, 21 Not applicable, 4 Phase 4.
Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 500 | 2026-11-25 | 2026-11-04 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer | Phase 3 | Not yet recruiting | Fudan University | 394 | 2026-11-15 | 2026-11-12 |
| First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma Sintilimab, Ipilimumab N01, Bevacizumab - Peritoneal Mesothelioma, First-line Therapy | Phase 2 | Not yet recruiting | Fudan University | 19 | 2026-10-30 | 2026-10-23 |
| A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer Ipilimumab N01, Sintilimab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 36 | 2026-10-20 | 2026-10-16 |
| ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 600 | 2026-10-20 | 2026-11-16 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer Sintilimab, Capecitabine, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Anhui Medical University | 50 | 2026-10-01 | 2026-10-05 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II) - Stomach Neoplasms, Gastric Cancer | Phase 2 | Not yet recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 20 | 2026-10-01 | 2026-09-14 |
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 288 | 2026-09-30 | 2026-08-12 |
| QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ QLS31905, Sintilimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 560 | 2026-09-24 | 2026-10-19 |
| Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer Tafolecimab, Sintilimab - Colon Cancer, PCSK9 Inhibitor | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 70 | 2026-09-20 | 2026-09-25 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-09-08 | 2026-11-09 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B Sintilimab, Pegylated Interferon-α 2b, Nucleos(t)ide Analogues - Chronic Hepatitis B | Not applicable | Not yet recruiting | Beijing 302 Hospital | 60 | 2026-09-01 | 2026-09-09 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 32 | 2026-09-01 | 2026-09-02 |
Showing 20 of 504. Sign in to see all of them.
Carcinoma, Hepatocellular (65) · Stomach Neoplasms (48) · Carcinoma, Non-Small-Cell Lung (39) · Colorectal Neoplasms (25) · Esophageal Squamous Cell Carcinoma (20) · Lung Neoplasms (13) · Nasopharyngeal Carcinoma (13) · Rectal Neoplasms (12) · Esophageal Neoplasms (11) · Neoplasm Metastasis (9) · Pancreatic Neoplasms (9) · Neoplasms (8) · Recurrence (8) · Squamous Cell Carcinoma of Head and Neck (8) · Cholangiocarcinoma (6)
Sun Yat-sen University (52) · Fudan University (43) · Innovent Biologics (Suzhou) Co. Ltd. (41) · Tianjin Medical University Cancer Institute and Hospital (24) · Zhejiang Cancer Hospital (15) · The First Affiliated Hospital with Nanjing Medical University (13) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (12) · Second Affiliated Hospital, Zhejiang University, School of Medicine (11) · West China Hospital (11) · Ruijin Hospital (8) · Sichuan University (8) · Tongji Hospital (8) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (8) · Peking Union Medical College Hospital (7) · RenJi Hospital (7)
China (439) · United States (6) · Australia (3) · France (2) · Spain (2) · Belgium (1) · Germany (1) · Hungary (1) · Switzerland (1) · United Kingdom (1)
Peng Wang, MD (7) · Kangshun Zhu, Dr. (3) · You Lu, MD (3) · Hao Zeng, Doctor (2) · Jason Wu (2) · Jing-wen Wang, M.D. (2) · Kangshun Zhu, MD (2) · Lin Wu (2) · Mian Xi, MD (2) · Yi-Long Wu (2) · Ying Cheng (2) · Yunpeng Liu, PhD (2) · Ze-yang Ding, M.D. (2) · Zhen Zhang, M.D, PH.D (2) · Aiping Zhou, M.D. (1)
PMID 32781263, PMID 34143971, PMID 34702811, PMID 35440464, PMID 15496622, PMID 18559976, PMID 19387333, PMID 20548096, PMID 20728210, PMID 21879261, PMID 22646630, PMID 24094768, PMID 24403232, PMID 25240821, PMID 25991832, PMID 26291008, PMID 26480849, PMID 26884585, PMID 27389519, PMID 28314688, PMID 28493288, PMID 28823862, PMID 29095678, PMID 29229461, PMID 29366520, PMID 29398921, PMID 29543938, PMID 29658856, PMID 29787422, PMID 29966520, PMID 29967015, PMID 30089078, PMID 30119083, PMID 30172698, PMID 30207593, PMID 30285222, PMID 30558224, PMID 30612710, PMID 30620669, PMID 30718072, PMID 30770362, PMID 30826965, PMID 30955977, PMID 30975638, PMID 31209394, PMID 31294749, PMID 31320661, PMID 31378236, PMID 31402780, PMID 31463890